• Cerus (Concord, California) said that Carol Moore was named VP of regulatory affairs and quality. Prior to joining Cerus, Moore was VP of worldwide regulatory affairs for Bayer. Cerus makes the Intercept blood system to enhance blood safety.

• Minrad International (Orchard Park, New York) reported that its board approved the appointment of David DiGiacinto as president/CEO. DiGiacinto's appointment is the first step in a transition in which he will become CEO beginning on January 1, 2009. William Burns will continue to serve as CEO through the end of the year and will serve as chairman until the company's 2009 annual meeting. DiGiacinto is joining Minrad from Spencer Trask & Co. Minrad is an interventional pain management company with real-time image guidance and anesthesia and analgesia product lines.

• Synthetic Blood International (SBI; Costa Mesa, California) reported new management roles and responsibilities for company board members to succeed the late Robert Larsen (Medical Device Daily, March 26, 2008). Chris Stern, who is the chairman of the board, assumes responsibilities of CEO. At the same time, Richard Kiral, PhD, VP of R&D, becomes president/CEO. Stern is best known for his writings and lectures on management techniques and managing multilingual and multinational companies. Kiral has served the company as VP of R&D since 1999 and has been responsible for developing products from SBI's perfluorocarbon technology platforms. SBI makes pharmaceuticals and medical devices in the field of oxygen therapeutics and continuous substrate monitoring.

• StatCom (Atlanta) said Michael Holland will lead StatCom's sales team as it launches a targeted sales and marketing program. For the past five years Holland has held executive roles leading sales, marketing and business development at several start-up companies. StatCom is a provider of patient flow logistics and tracking solutions.